N-Acetyl-O-phosphono-Tyr-Glu-Glu-Ile-GluPhosphopeptide ligand for src SH2 domain CAS# 159439-02-8 |
2D Structure
- Phellodendrine chloride
Catalog No.:BCN5934
CAS No.:104112-82-5
- Lobetyolin
Catalog No.:BCN5894
CAS No.:136085-37-5
- Neferine
Catalog No.:BCN6338
CAS No.:2292-16-2
- Liensinine
Catalog No.:BCN6337
CAS No.:2586-96-1
- Orientin
Catalog No.:BCN4984
CAS No.:28608-75-5
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 159439-02-8 | SDF | Download SDF |
PubChem ID | 42628614 | Appearance | Powder |
Formula | C32H46N5O17P | M.Wt | 803.71 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 1 mg/ml in water | ||
Sequence | YEEIE (Modifications: Tyr-1 = pTyr with C-terminal Ac) | ||
Chemical Name | (2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-(4-phosphonooxyphenyl)propanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]amino]pentanedioic acid | ||
SMILES | CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CC1=CC=C(C=C1)OP(=O)(O)O)NC(=O)C | ||
Standard InChIKey | QQEKQSBIEKQXQS-PSCZMIBCSA-N | ||
Standard InChI | InChI=1S/C32H46N5O17P/c1-4-16(2)27(31(48)36-22(32(49)50)11-14-26(43)44)37-29(46)21(10-13-25(41)42)34-28(45)20(9-12-24(39)40)35-30(47)23(33-17(3)38)15-18-5-7-19(8-6-18)54-55(51,52)53/h5-8,16,20-23,27H,4,9-15H2,1-3H3,(H,33,38)(H,34,45)(H,35,47)(H,36,48)(H,37,46)(H,39,40)(H,41,42)(H,43,44)(H,49,50)(H2,51,52,53)/t16-,20-,21-,22-,23-,27-/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Phosphopeptide ligand for the src SH2 domain (IC50 = 1 μM). Blocks src interactions with EGFR and FAK. |
N-Acetyl-O-phosphono-Tyr-Glu-Glu-Ile-Glu Dilution Calculator
N-Acetyl-O-phosphono-Tyr-Glu-Glu-Ile-Glu Molarity Calculator
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Everolimus (RAD001)
Catalog No.:BCC3594
CAS No.:159351-69-6
- MPDC
Catalog No.:BCC6873
CAS No.:159262-32-5
- PNU 22394 hydrochloride
Catalog No.:BCC7285
CAS No.:15923-42-9
- Isokaempferide
Catalog No.:BCN3790
CAS No.:1592-70-7
- L-NIO dihydrochloride
Catalog No.:BCC6689
CAS No.:159190-44-0
- MM 77 dihydrochloride
Catalog No.:BCC6854
CAS No.:159187-70-9
- L-755,507
Catalog No.:BCC7282
CAS No.:159182-43-1
- CARIPORIDE
Catalog No.:BCC6432
CAS No.:159138-80-4
- 3F8
Catalog No.:BCC6112
CAS No.:159109-11-2
- F1839-I
Catalog No.:BCN6450
CAS No.:159096-49-8
- 6-Benzyloxyindole
Catalog No.:BCC8769
CAS No.:15903-94-3
- Wedelobatin B
Catalog No.:BCN6730
CAS No.:1589488-35-6
- Enfuvirtide
Catalog No.:BCC5641
CAS No.:159519-65-0
- Fluconazole mesylate
Catalog No.:BCC4236
CAS No.:159532-41-9
- GR 55562 dihydrochloride
Catalog No.:BCC6913
CAS No.:159533-25-2
- Daminozide
Catalog No.:BCC1514
CAS No.:1596-84-5
- 3,4-Secotirucalla-4(28,7,24-triene-3),26-dioic acid
Catalog No.:BCN1549
CAS No.:159623-48-0
- Saropyrone
Catalog No.:BCN7692
CAS No.:159650-12-1
- Wikstrol A
Catalog No.:BCN7938
CAS No.:159736-35-3
- ISRIB (trans-isomer)
Catalog No.:BCC5340
CAS No.:1597403-47-8
- Ibutamoren Mesylate
Catalog No.:BCC1638
CAS No.:159752-10-0
- Fmoc-Lys(Ac)-OH
Catalog No.:BCC3514
CAS No.:159766-56-0
- Ulipristal
Catalog No.:BCC4944
CAS No.:159811-51-5
- Sikokianin C
Catalog No.:BCN6827
CAS No.:159813-69-1
Design and characterization of non-phosphopeptide inhibitors for Src family SH2 domains.[Pubmed:12217360]
Bioorg Med Chem Lett. 2002 Oct 7;12(19):2711-4.
The development of novel non-phosphopeptide inhibitors for the Src family SH2 domain is described. Several commercially available hydroxyl aromatic acids have been appended off the N-terminus of pYEEIE and the potent phosphopeptide inhibitors of GST-Lck-SH2 were identified via ELISA. The most potent inhibitor, caffeic acid-pYEEIE, exhibited approximately 30-fold more binding activity than Ac-pYEEIE. Non-phosphopeptides were synthesized by replacing phosphotyrosine of caffeic acid-pYEEIE with tyrosine or 3,4-dihydroxyphenylalanine (DOPA). Caffeic acid-DOPA-EEIE that did not contain phosphotyrosine and its isosteres exhibited less than 20 times decreased binding affinity for GST-Lck-SH2 than Ac-pYEEIE. Moreover, it had a similar binding affinity for the GST-Lck-SH2, GST-Src-SH2, and GST-Fyn-SH2 domains. This study showed that the pY-1 positions of the phosphopeptide inhibitors and of the non-phosphopeptide inhibitors played an important role in the binding for the SH2 domain and that the non-phosphopeptide inhibitor must be a new lead in the development of SH2 inhibitors.
Potent dipeptide inhibitors of the pp60c-src SH2 domain.[Pubmed:9599239]
J Med Chem. 1998 May 21;41(11):1894-908.
The design, synthesis, and evaluation of dipeptide analogues as ligands for the pp60c-src SH2 domain are described. The critical binding interactions between Ac-Tyr-Glu-N(n-C5H11)2 (2) and the protein are established and form the basis for our structure-based drug design efforts. The effects of changes in both the C-terminal (11-27) and N-terminal (51-69) portions of the dipeptide are explored. Analogues with reduced overall charge (92-95) are also investigated. We demonstrate the feasibility of pairing structurally diverse subunits in a modest dipeptide framework with the goal of increasing the druglike attributes without sacrificing binding affinity.
Peptide inhibitors of src SH3-SH2-phosphoprotein interactions.[Pubmed:7527393]
J Biol Chem. 1994 Dec 16;269(50):31711-9.
Activated pp60c-src has been implicated in a number of human malignancies including colon carcinoma and breast adenocarcinoma. Association of the src SH2 domain with tyrosine-phosphorylated proteins plays a role in src-mediated signal transduction. Inhibitors of src SH2 domain-phosphoprotein interactions are, thus, of great interest in defining the role(s) of src in signal transduction pathways. To facilitate such studies, an enzyme-linked immunosorbent assay (ELISA) was developed to detect inhibitors of src SH2-phosphoprotein interactions. This assay measures inhibition of binding of a fusion construct (glutathione S-transferase src SH3-SH2) with autophosphorylated epidermal growth factor receptor tyrosine kinase domain. Activities of phosphopeptide segments derived from potential src SH2 cognate phosphoprotein partners were determined, with the focal adhesion kinase-derived segment VSETDDY*AEIIDE yielding the highest inhibitory activity. Structure activity studies starting from acetyl (Ac)-Y*EEIE have identified Ac-Y*Y*Y*IE as the most active compound screened in the ELISA. This compound is at least 20-fold more active than the parent peptide Ac-Y*EEIE. A high resolution (2 A) crystal structure of human src SH2 complexed with Ac-Y*EEIE was obtained and provided a useful framework for understanding the structure-activity relationships. Additionally, Ac-Y*EEIE was able to block interactions between src and its cellular phosphoprotein partners in vanadate-treated cell lysates from MDA-MB-468 breast carcinoma cells. However, it is unable to abrogate proliferation of MDA-MB-468 cells in culture, presumably because of poor cell penetration and/or lability of the phosphate group on tyrosine.